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Abstract
Background: The association between fibromyalgia and irritable bowel syndrome is well-established. Alterations in
the composition and diversity of the gut microbiome in irritable bowel syndrome have been reported, however,
this association is poorly understood in fibromyalgia.
Our aim was to summarise the research reporting on the gastrointestinal microbiome and its biomarkers in people
with fibromyalgia.
Methods: A systematic review of published original research reporting on the gastrointestinal microbiota and its
biomarkers in adults with a diagnosis of fibromyalgia was undertaken.
Results: From 4771 studies, 11 met our inclusion criteria and were separated into four main groups: papers
reporting Helicobacter pylori; other gut bacterial markers; metabolomics and other biomarkers, which included
intestinal permeability and small intestinal bacterial overgrowth.
Conclusion: The results suggest there is a paucity of quality research in this area, with indications that the gut
microbiota may play a role in fibromyalgia within the emerging field of the gut-musculoskeletal axis. Further
investigations into the relationship between the gut microbiota, gut dysfunction and fibromyalgia are warranted.
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Background
It has been almost half-century since the term fibro-
myalgia replaced fibrositis [1], yet the condition remains
idiopathic, poorly understood and difficult to treat [2].
Its cardinal symptom is pain, which must be both wide-
spread and chronic to meet the current diagnostic
criteria.
The prevalence of fibromyalgia shows large variability.
A review of 39 studies conducted across 19 countries in-
dicates prevalence ranges from 0.2 to 6.6% [3]. The asso-
ciated morbidity is not insignificant and the costs, both
direct and indirect, contribute to a significant socioeco-
nomic burden [4].
Without laboratory evaluations that contribute to the
diagnosis of the condition, it is also difficult to diagnose
[5]. Therefore, clinical presentation of the typical pain
and the presence of associated somatic and psychological
symptoms form the basis of current diagnosis.
To date the pathophysiology of fibromyalgia remains
elusive. No causative agent has been identified, however,
a role for a range of different infections has been sug-
gested [6]. Nervous system dysfunction is implicated and
neurotransmitters are the targets of a number of drugs
approved for fibromyalgia [7]. Recently, Albrecht and
colleagues have suggested a possible role for microglial
activation and neuroinflammation [8]. Pathological
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changes in epidermal nerve fibres has also been impli-
cated, with evidence for the association nearing 50% [9].
The role of oxidative stress, autoimmune markers, prote-
omics, genetics and a range of hormones have all been
implicated with inconsistent results [10]. Inflammation
has never been clearly identified. A systematic review
and meta-analysis of 13 studies reporting inflammatory
biomarkers in fibromyalgia found only plasma
interleukin-6 (IL-6) to be higher in patients, compared
to controls.
Fibromyalgia is associated with a range of somatic
symptoms and gastrointestinal disorders. Our group
have recently conducted a systematic review of the co-
morbidity of FGID in fibromyalgia and found this area
to be under-explored, with the majority of studies focus-
ing on irritable bowel syndrome (IBS) [11]. IBS has been
associated with alterations in the composition and diver-
sity of the gastrointestinal microbiota [12]. Individuals
with both fibromyalgia and IBS report higher symptom
severity and poorer quality of life [13, 14]. Interest in the
role of the gastrointestinal microbiome on both the gut-
brain axis and systemic disorders has increased exponen-
tially in recent years and a comprehensive review of this
topic as it relates to fibromyalgia is warranted.
The aim of this systematic review was to examine and
summarise the research reporting on the composition
and diversity of the gut microbiome and associated bio-
markers in adults with fibromyalgia.
Methods
This review was registered with PROSPERO (https://
www.crd.york.ac.uk/PROSPERO/). [registration number
pending].
Data sources
A search of Medline, CINAHL, Embase and Web of Sci-
ence databases was made using the terms in Table 1,
conducted over 06–08 August 2019. Results were
exported into EndNote X9.2 (Thomson Reuters Inc.,
Philadelphia, PA, USA.) and duplicate records deleted.
Table 1 Search used for the Medline database to identify literature reporting on fibromyalgia and terms related to gut microbiome
and/or biomarkers of gut bacteria
Search Search term(s)
1. fibromyalgia.mp. or Fibromyalgia/ or fibromyositis or fibrositis or "muscular rheumatism"
2. "c-reactive protein.mp. or C-Reactive Protein/ or CRP.mp. or interleukin.mp. or exp. Interleukins/ or IL-1B.mp. or IL-6.mp. or IL-10.mp. or IL-
17.mp. or cytokine* or cytokines).mp. or exp. Cytokines/ or chemokine.mp. or tumor necrosis factor.mp. or exp. Tumor Necrosis Factor-alpha/
or TNF*.mp. or exp. Creatine Kinase/ or ("creatine kinase" or protease).mp. or ((metabolic or lactic) and acidosis).mp. or acidosis/ or exp.
acidosis, lactic/ or anion gap.mp. or Acid-Base Equilibrium/
3. ((lactulose adj3 mannitol) or (lactulose and mannitol)).mp. or (zonulin or occludin).mp. or Occludin/ or citrulline.mp. or Citrulline/ or zonula
occluden*.mp. or lipopolysaccharide*.mp. or exp. Lipopolysaccharides/ or LPS.mp. or flagellin.mp. or (endox* or (bacter* adj3 toxin*)).mp. or
(histamine or tryptase).mp. or (calprotectin or eosinophil protein x).mp. or (secretory IgA or sIgA).mp. or *Immunoglobulin A, Secretory/ or
(((butyric or acetic or propionic or lactic) and acid) or (butyrate or acetate or propionate or lactate)).mp. or exp. Fatty Acids, Volatile/ or short
chain fatty acid*.mp. or SCFA.mp. or (trimethylamine N-oxide or TMAO).mp. or Ammonia/ or (ammonia or hippuric or 2-hydroxyisobutyric).
mp. or (creatine or succinic or taurine or serine or arginine or glutam*).mp. or Methane/ or methane.mp. or Hydrogen/ or hydrogen.mp. or
"hydrogen sul?ide".mp. or exp. Biomarkers/ or biomarker*.mp. or metabolite*.mp. or metabolome.mp. or exp. Metabolome
4. 2 or 3
5 (((gastrointestin* or gut) adj3 microbio*) or (intestin* adj3 flora) or (intestin* adj3 bacteria)).mp. or exp. gastrointestinal microbiome/ or
gastrointestinal microbiome.mp. or microbio*.mp. or exp. Microbiota/ or exp. Mycobiome/
6. Lactobacillus/ or lactobacill*.mp. or Bifidobacterium/ or bifidobacter*.mp. or exp. Probiotics/ or probiotic*.mp. or (akkermansia or f?
calibacter*).mp. or (clostrid* or bilophil*).mp. or Bilophila/ or Desulfovibrio/ or desul?ovibrio.mp. or methano*.mp. or exp.
Methanobrevibacter/ or (proteobacter or citrobacter or actinobacter*).mp. or (Roseburia or Eubacteri* or Subdoligranulum or Anaerostipes or
Lachnospiraceae).mp. or exp. Eubacteria/ or exp. Prevotella/ or prevotella.mp. or klebsiella.mp. or exp. Klebsiella/ or collinsella.mp. or
veillonella.mp. or Veillonella/ or exp. Bacteroidetes/ or bacteroid*.mp. or firmicutes.mp. or Firmicutes/
7. exp Gram-Positive Bacteria/ or exp. Gram-Negative Bacteria/ or ((gram-negative or gram-positive) and bacteria).mp. or exp. aerobic bacteria/
or (aerobic adj3 bacter*).mp. or exp. anaerobic bacteria/ or (anaerobic adj3 bacter*).mp. or helicobacter pylori.mp. or Helicobacter pylori/ or
"H. pylori".mp. or exp. Candida/ or candida.mp. or exp. Saccharomyces/ or saccharomyces.mp. or rhodotorula.mp. or Rhodotorula/ or
yeast.mp.
8. 5 or 6 or 7
9. 4 or 8
10. 1 and 9
11. Limit 10 to English language, Humans, Adults
12. Limit 11 to publication date: 01 January 1976a to present
athe year "fibromyalgia" became the official term for the condition 1. Inanici F, Yunus MB: History of fibromyalgia: past to present. Current Pain and Headache
Reports 2004, 8(5):369–378
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Study selection
Further screening to remove conference abstracts, stud-
ies involving children (< 18 years of age), animals, re-
views, case reports or papers irrelevant to our objectives.
Full-text articles were retrieved and linked to the corre-
sponding EndNote record. Reference lists of included ar-
ticles were reviewed for other studies relevant to our
objectives. Articles were scanned for diagnostic criteria
used; those not specifying accepted guidelines for diag-
nosis were excluded. We also excluded papers reporting
systemic biomarkers not evaluated in the context of
gastrointestinal symptoms or gut flora.
The selection process is presented in Fig. 1, utilising
the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) flow diagram [15].
Data extraction
The following data was extracted to a Microsoft® Excel®
spreadsheet: lead author, year, country of publication,
gender and age of cohort, diagnostic criteria used for
fibromyalgia, bacteria or biomarker thereof reported,
summary of results.
Quality assessment
All studies were reviewed by two authors (SE and JEH)
who screened for inclusion criteria and conducted a
quality assessment using the Joanna Briggs critical ap-
praisal tool “Checklist for case-control studies” [16], with
additional quality criterion including: diagnostic criteria
used to identify fibromyalgia, the description of cohort/s,
and evidence that ethics/consent had been granted, giv-
ing a total of 16 criteria for evaluation. Scores were then
converted to percentages for reporting.
Results
A total of 4771 articles were retrieved. The PRISMA
flow diagram (Fig. 1) shows the selection process and
number of studies included and excluded at each step to
arrive at the final eleven studies, conducted in 7 coun-
tries, included in this analysis. There was a high degree
of heterogeneity across the studies, which were of vari-
able quality (Table 2).
A total of 618 subjects with fibromyalgia (90% female
[n = 554]), and 635 controls, of whom 180 (29%) had other
health conditions were included. Two papers presented
Fig. 1 PRISMA Flow Diagram Showing Study Selection Process
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different data from the same cohort which is included
once in the population totals.
Eight papers evaluated markers for specific gut mi-
crobes: five reported on Helicobacter pylori [19–23], and
are reported as a group. Four described biomarkers of
the gut microbiota [18, 19, 26, 27]; four explored meta-
genomics/metabolites or metabolomics [24–27], and
three [17–19] reported other biomarkers, such as intes-
tinal permeability. Four studies [18, 19, 26, 27] examined
more than one type of biomarker and so are included in
each of the appropriate sections below.
A summary of the key information of the 11 included
articles is presented in Table 2.
Helicobacter pylori
Table 3 details results of five studies evaluating H. pylori
in patients with fibromyalgia.
Biopsy results from Rodrigo’s study also revealed sig-
nificantly higher rates of intraepithelial lymphocytosis
(IEL) (Marsh stage 1) and villous atrophy (Marsh stage
3) in the group with fibromyalgia plus IBS, compared to
the IBS-only group (56% vs 16 and 7% vs 2%, respect-
ively), (both p < 0.001). As a result of this investigation,
seven of the 104 patients with fibromyalgia were subse-
quently diagnosed with coeliac disease [22].
Gastrointestinal microbiota and antibodies
Four studies are included in this group, as presented in
Table 4. In addition to serum antibodies to two gut-
specific organisms, Goebel et al., [19] assessed results
against measures of intestinal permeability (IP) (see
Table 6). Three studies evaluated the microbial compos-
ition of faecal specimens, however, all employed differ-
ent methodology.
Metabolomics/metabolites
The urinary microbial metabolism data reported in two
of the studies included in this review were obtained from
the same cohort [24, 25]. Two other studies evaluated
serum markers for a range of metabolites, proteins and
gene expression [26, 27], and three compared patients
with more than one type of control [24, 25, 27]. These
are summarised in Table 5.
Alterations in levels of urine metabolites reported in the
first of Malatji’s papers [24] were predicted to be associ-
ated with gut bacteria. Employing a more targeted ap-
proach, the same team later reported the presence of the
monosaccharides sorbose, rhamnose and tagatose which
are typically not found in human urine [25]. One mechan-
ism proposed by the authors for their presence was bac-
terial degradation of plant-derived carbohydrates.
Table 2 Characteristics of 11 papers investigating biomarkers related to the gastrointestinal microbiome in subjects with
fibromyalgia
Author (Year) Country Cohort Study Type FMS
criteria
Controls
n, Type
Biomarker/s Quality
Assessment
%
N (% female) Age
Pimentel (2004) [17] USA 42 (86) 46.6 ± 0.3 Case-control ACR 1990 22 IBS SIBO 53.1
Michalsen (2005) [18] Germany 35 (91) 52.0 ± 10.0
51.6 ± 13.3a
Case-control ACR 1990 16 RA Stool culture
Stool pH
sIgA
56.3
Goebel (2008) [19] Germany 40c (80) 48 ± 11 Case-control ACR 1990 57 HC
17 CRPS
H. pyloriBacteria
(serum antibodies)
Intestinal permeability
75.0
Akkaya (2011) [20] Turkey 65 (100) 36.21 ± 7.42 Case-control ACR 1990 41 HC H. pylori 75.0
Olama (2013) [21] Egypt 100 (100) 33.2 ± 4.36 Case-control ACR 1990 100 HC H. pylori 81.3
Rodrigo (2013) [22] Spain 104 (89) 50 ± 8b Case-control ACR 1990 125 IBS H. pylori 75.0
Gezici (2014) [23] Turkey 32 (88) 38.5 ± 8.6 Prospective ACR 1990 – H. pylori 43.8
Malatji (2017) [24] South Africa 18 (100) 45.5 Case-control ACR 1990 11 FC
10 MC
41 YC
Metabolomics 75.0
Malatji (2019) [25] South Africa 17 (100) 45.5 (ns) Case-control ACR 1990 11 FC
10 MC
41 YC
Metabolomics 75.0
Clos-Garcia (2019) [26] Spain 105 (70) 52.52 ± 10.3 Case-control ACR 1990 54 HC Microbiome
Metabolomics
81.3
Minerbi (2019) [27] Canada 77 (100) 46 ± 8 Case-control ACR 2016 11 FC
20 HM
48 UC
Microbiome
Metabolites
87.5
Key: ACR American College of Rheumatology; FMS Fibromyalgia; JB Joanna Briggs; ns not stated; IBS irritable bowel syndrome; SIBO small intestinal bacterial
overgrowth; RA rheumatoid arthritis; HC healthy controls; CRPS chronic regional pain syndrome; FC family controls; MC matched controls; YC young controls; HM
household members; UC unrelated controls; a = age (SD) of FMS in group B; b = age of IBS cohort 51 ± 8; c = 40 FMS patients, serology data for 33.
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Clos-Garcia et al. [26] also concluded that some of the
altered metabolites, as well as both up- and down-
stream products, may be bacterial in origin.
Other biomarkers
Three studies [17–19] outlined in Table 6, evaluated
markers not included in the groups above. In Michal-
sen’s study [18], fibromyalgia and rheumatoid arthritis
patients were allocated into two separate arms, each of
which undertook a different dietary intervention (either
a Mediterranean diet or fasting).
Pimentel et al. [17] investigated the prevalence of small
intestinal bacterial overgrowth (SIBO) in patients with
fibromyalgia, IBS and normal controls. Both peak and
area-under-the-curve (AUC) values for hydrogen pro-
duction where significantly higher in those with fibro-
myalgia compared to controls both with and without
IBS.
Table 4 Results from 4 studies Investigating Gastrointestinal Microbiota Taxa and Antibodies
Author (Year) Patients
Controls
Material & Procedure Results p-value Other
Michalsen (2005) [18] 21 FMS
9 RA
Faeces
Culture
No differences n.s pre- vs post-fasting
14 FMS
7 RA
Faeces
Culture
No differences n.s pre- vs post-MedDiet
Goebel (2008) [19] 33 FMS17 CRPS 57
HC
Serum antibodies
Yersinia or Campylobacter
FMS 27% positive
CRPS 13%
HC Not tested
NR Trend for seropositivity
assoc. with IP (Table 4)
Minerbi (2019) [27] 77 FMS
11 FC
20 HM
48 UC
Faeces
16S rRNA gene
(V5-V6 region) / metagenome
↓ Faecalibacterium
and Bacteroides, ↑
Intestinimonas,
Flavonifractor,
Butyricoccus
Eisenbergiella and
Enterobacter.
< 0.01 Non-significant differences
in sample diversity
Variance FMS vs UC
Clos-Garcia (2019)
[26]
105 FMS
54 HC
Faeces
16S rDNA microbiome(V3–V4
region)
FMS: Absent families:
Bifidobacteriaceae
and Bacteroidales↑
Dorea, Roseburia,
Alistipes, Papillibacter,
Subdoligranulum↓
Bacteroides,
Bifidobacterium,
Eubacterium, Clostridium
All p ≤
0.05
Controls had higher
diversity
Key: n.s. not statistically significant; NR not reported; FMS Fibromyalgia; RA rheumatoid arthritis; HC healthy controls; CRPS chronic regional pain syndrome; IP
intestinal permeability; FC family controls; HM household members; UC unrelated controls.
Table 3 Results from 5 Studies Investigating H. pylori
Author (Year) Cohort Material H. pylori
marker
H. pylori positive (%)
FMS Controls p- value
Goebel (2008) [19] 33 FMS
17 CRPS
57 HC
Serum antibodies
IgA or IgG
33.0 HC: NT CRPS: 47.0 n.s.
Akkaya (2011) [20] 65 FMS
41 HC
Serum antibodies
IgA
IgG
30.8
67.7
17.1
43.9
0.169
0.025
Olama (2013) [21] 100 FMS
100 HC
Serum antibodies
IgA
IgG
50.0
68.0
24.0
32.0
< 0.001
< 0.001
Rodrigo (2013) [22] 104 FMS
125 IBS
Gastroduodenal
biopsyH&E + Giemsa
staining, polyclonal
anti-H. pylori antibody,
microbial cultures
42.0 46.0 n.s.
Gezici (2014) [23] 41# FMS Gastric biopsy
Culture
78.0 – –
Key: # all had dyspepsia; FMS fibromyalgia; HC healthy controls; CRPS chronic regional pain syndrome; IBS irritable bowel syndrome; NT not tested; NA not
reported; n.s. not statistically significant.
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Both small intestinal and gastroduodenal permeability
was evaluated in Goebel’s study [19] employing
lactulose-mannitol recovery testing. Follow-up data col-
lected in the week after testing, while not available for
all participants, revealed 2 days of moderate-to-severe
diarrhoea in 13 of the 31 subjects.
Gut biomarkers and interventions associated with
fibromyalgia symptoms
Studies exploring the relationship between H. pylori and
fibromyalgia were conflicting. Akkaya’s study found no
differences in regards to any of the clinical features eval-
uated [20], whereas Olama et al., described significant
associations between H. pylori immunoglobulin-G (IgG)
-positive patients and disease markers, including: post-
exertion pain, morning stiffness, confusion, mood, ten-
sion headache, sleep disturbance, dyscognition, changes
in appetite and fatigue (all p < 0.05) [21]. Gezici’s group
reported a significant reduction in pain, as evaluated by
the number of tender points, following H. pylori eradica-
tion (p < 0.001) [23].
A significant association between the differential abun-
dance of several taxa and some indices of the 2016 ACR
Fibromyalgia criteria (such as pain intensity, widespread
pain index (WPI), dyscognition), and quality of life
scores (including fatigue) was reported by Minerbi’s
group (all p < 0.05). Some operational taxonomic units
were found to be inversely related to many of the same
Table 5 Results from 3 studies (4 papers) Investigating Metabolites and Metabolomics
Author (Year) Subjects
Controls
Material
Biomarker
FMS Subjects P value for diff
Malatji (2017) [24] 18 FMS11
FC10 MC41 YC
UrineNMR
metabolome
Compared to YC
↑ hippuric acid
↑ succinic acid
↑ lactic acid ↑
2-Hydroxyisobutyric
acid
p = 0.0966(ns)
p = 0.0001 (MW)
p = 0.0044
p = 0.0001
Malatji (2019) [25] 17 FMS11
FC10 MC41 YC
UrineGC-MS
metabolome
↑ 14 metabolites c.f.
MC↑ 4-hydroxyisobutyric
acid c.f. MC & YC
↑ arabinose c.f. MC
All < 0.001
(MW & BF)
p = 0.00109
Minerbi (2019) [27] 77 FMS11 FC20
HM48 UC
Serum
Metabolites
Compared to UC:
↑serum butyrate ↓serum
propionic acid
↓isobutyric acid
p = 0.005p = 0.006
p = 0.056 (ns)
Clos-Garcia (2019) [26] 105 FMS54 HC Serum
Metabolome
↓ gadC, glnA, glsA2,
gadB1, gadB2↑ lysine,
ornithine
↑threonine, homoserine,
glutamine, and argininea
p < 0.05
p < 0.05
p < 0.001
Key: FMS Fibromyalgia; NMR nuclear magnetic resonance spectrometry; GC-MS gas chromatography–mass spectrometry: HC healthy controls; FC family controls;
MC matched controls; YC young controls; HM household members; UC unrelated controls; c.f. compared to; MW Mann Whitney test; BF Bonferroni-Holm test; ns
not significant; gad glutamate decarboxylase; gln glutamine synthetase; gls glutaminase: a all identified as likely of bacterial origin.
Table 6 Results From 3 Studies Investigating Other Gut-Related Markers
Author
(Year)
Cohort Material /
Biomarker
Results p-value for diff
FMS Controls
Pimentel
(2004) [17]
42 FMSa
111 IBS
15 HC
Breath(SIBO) 100% IBS 84%
HC 20%
< 0.05
< 0.0001
Michalsen
(2005) [18]
21 FMS9 RA StoolpH &
sIgAfollowing
fasting
No differences
between FMS
vs RA groups
or with different
interventions
n.s.
14 FMS7 RA StoolpH &
sIgAfollowing
MedDiet
n.s.
Goebel
(2008) [19]
40 FMS
17 CRPS
57 HC
UrineGD
permeabilitySI
permeability
32.5%37.5% CRPS 35.3%, HC
5%CRPS 17.6%,
HC 0%
< 0.0001b < 0.0002&
Key: a = 22 (54%) had IBS; b = p-value compared to controls; FMS Fibromyalgia; CRPS chronic regional pain syndrome; HC healthy controls; GD gastroduodenal; SI
small intestine; IBS irritable bowel syndrome; RA rheumatoid arthritis; MedDiet Mediterranean Diet; SIBO small intestinal bacterial overgrowth; n.s. not significant.
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indicators in unrelated controls [27]. Genus-level com-
position of the gut microbiome weakly correlated to pain
indicators in Clos-Garcia’s report, with the strongest
correlations in micro ribonucleic acid (miRNA) data,
followed by serum proteins and metabolomics [26].
Malatji et al. (2017) described specific combinations of
metabolites (creatine & succinic acid +/− taurine) relat-
ing to pain scores and loss of energy [24]. In spite of in-
dicating that 88% of their small cohort had some degree
of gastrointestinal dysfunction, possibly classified as IBS,
details were not described; nor was any attempt made to
relate digestive symptoms to the measured metabolites
[25].
Pain scores correlated significantly with both peak and
AUC hydrogen gas production (r = 0.42, p < 0.01 and r =
0.37, p < 0.05) on breath testing by Pimentel’s group
[17]. Treatment of SIBO resulted in significant reduc-
tions in pain (p < 0.05). A non-significant improvement
in clinical measures was described in those patients fol-
lowing the fasting regime in Michalsen’s study [18], and
Goebel reported no association between IP and the pain
of either chronic regional pain syndrome (CRPS) or
fibromyalgia [19].
Discussion
We set out to systematically evaluate the literature
reporting data associated with the gut microbiota in
people with fibromyalgia. The review identified five
broad areas of research, but to date no single gut-
fibromyalgia biomarker has been validated. Some studies
demonstrated variability in markers associated with the
gut microbiota in patients with fibromyalgia compared
to healthy controls [24].
A wide range of research methods were detected and
lack of control for factors which may impact the bio-
markers being investigated was common. This included
failure to measure dietary patterns, smoking and drug
use. Importantly, of the included studies that evaluated
the composition of the gut microbiome, the methods
used were different, making comparisons problematic.
Some statistically significant differences were reported,
but due to the high degree of variability in both the
methods and markers evaluated, and the presence of im-
portant confounding factors, it is difficult to draw any
strong conclusions.
Helicobacter pylori
While several papers reported a relationship between H.
pylori and fibromyalgia the results are inconsistent. This
is probably due to a combination of different identifica-
tion methods and potential confounders, such as the re-
tention of patients in the control group with CRPS who
met fibromyalgia criteria [19].
None of the included studies utilised stool antigen or
13C-urea breath tests, and two [22, 23] performed cul-
ture following biopsy. Each of these are more reliable
than serology for H. pylori diagnosis [28].
Rodrigo et al., [22] described H. pylori at similar rates
in patients with IBS regardless of fibromyalgia status.
They also found coeliac disease (CD) in fibromyalgic pa-
tients at seven times the population rate and more than
double that reported in fibromyalgia elsewhere [29]. A
2012 study of 376 CD patients demonstrated 22% met
the 1990 ACR criteria for fibromyalgia [30] suggesting a
bidirectional relationship. In addition to its association
with CD and non-coeliac gluten sensitivity [31], IEL has
also been observed in H. pylori infections [32], although
other work has refuted this relationship [33]. No other
study included in this review evaluated subjects for CD
and neither CD nor IEL were in our search terms.
All subjects in Gezici’s Turkish study had fibromyalgia
and dyspepsia; 78% were positive for H. pylori [23], simi-
lar to the overall prevalence in that country [34].
Cytotoxin-associated gene A (CagA)-positive strains of
H. pylori are associated with a higher risk of dyspepsia
[35], but none of the studies included in this review eval-
uated virulence factors.
In summary, the studies provide weak evidence that H.
pylori may play a role in the symptomology of fibromyal-
gia, and while the exact relationship is uncertain, the im-
provement seen in pain scores just 3 weeks after
antibiotic treatment of H. pylori [23] warrants a system-
atic and rigourous investigation.
Gut microbiota
With rapid developments in microbiome technology
over the last two decades, it is not surprising our review
identified a diverse set of methodological approaches
employed in the assessment of antimicrobial communi-
ties. In 2005, bacterial culture was the accepted proced-
ure as DNA sequencing was in its infancy.
Michalsen’s study [18] demonstrated no differences in
the microbiota, however, this finding is limited by an ab-
sence of a healthy control group. Additionally, fibro-
myalgia and rheumatoid arthritis (RA) commonly
coexist [36], and it is unclear whether participants with
fibromyalgia were screened for RA.
A higher prevalence of positive antibodies to either
Yersinia enterocolitica or Campylobacter jejuni (data not
separated) in subjects with fibromyalgia compared to
those with CRPS is difficult to interpret [19]. While
these organisms commonly coexist, double-positivity for
H. pylori plus C. jejuni tends to be low [37] and H.pylori,
which may be protective against infection-induced diar-
rhoeal disease [38], was high in this cohort. Other fac-
tors, including use of H. pylori serology, absent data for
healthy controls, and seasonal variability of C. jejuni
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infection [37, 39], create further limitations to both the
interpretation and generalisability of these findings.
Imbalances in several genera were evident in the gut
microbiota data reported by both Minerbi and Clos-
Garcia [26, 27] (Table 4). Differences in sample collec-
tion protocols, the regions of amplification and the se-
quencing platforms makes comparability difficult.
In addition to assessing the microbiome, Minerbi et al.
[27] evaluated relationships with a range of other vari-
ables, including age, diet, drugs and physical activity. A
particular strength of the study was the inclusion of gen-
etic (first-degree relatives), environmental (household
cohabitants) and normal (non-related, not cohabiting)
controls and a dietary assessment for comparison be-
tween groups.
Several significant (p < 0.05), positive correlations were
reported between fibromyalgia symptoms and some taxa.
Differences in the microbiota were associated with the
diagnosis and symptoms of fibromyalgia. Of note, Bac-
teroides spp. was positively correlated with total symp-
tom score on the Fibromyalgia Impact Questionnaire
(FIQ) and the 2016 ACR diagnostic criteria. Increased
abundance of Parabacteroides merdae and a non-
significant increase in Akkermansia muciniphila was also
reported. These species appear to function synergistic-
ally, resulting in lower faecal gamma-glutamylation ac-
tivity, with a subsequent increase in hippocampal
gamma-Aminobutyric acid (GABA): glutamate [40].
While the relevance of this in fibromyalgia is unclear,
and an in depth discussion is outside the scope of this
review, it is interesting that glutamate, which functions
as an excitatory neurotransmitter and plays a role in
pain signaling [41, 42] has been reported at higher levels
in the insula [43] and in the interstitial compartment of
muscle of fibromyalgics [44]. Altered brain levels of glu-
tamate + glutamine have been associated with increased
pain sensitivity [45] and other research, identified lower
levels of the neurotransmitter GABA in the same area of
the brain [46].
Clos-Garcia et al. [26] used quantitative polymerase
chain reaction (qPCR) to determine bacterial gene ex-
pression related to glutamate metabolism and despite
finding five out of six glutamate degrading genes at sig-
nificantly higher levels in fibromyalgics than controls
(which would be expected to result in less glutamate),
higher serum levels of glutamate were found in the
fibromyalgia group. While this appears contradictory,
the higher serum glutamate is consistent with other data
reporting a role for glutamate in the central nervous sys-
tem (CNS) [47] and in pain signaling [41]. The bacteria
involved in glutamate and GABA metabolism in these
two studies were different: Bifidobacterium and Lactoba-
cillus in Clos-Garcia’s study [26], and Akkermansia
muciniphila and Parabacteroides spp., in Minerbi’s [27].
These differences are likely to be attributable to the re-
gion of the genome sequenced. Clos-Garcia’s group also
described a “discrete” lower bacterial diversity in their
patients, and higher abundance of several butyrate pro-
ducers, congruent with findings of higher levels of the
butyrate in the serum.
A high rate of drug use, both prescription and comple-
mentary medicines, was reported in Clos-Garcia’s study.
Data provided in their Supplemental Table 1, detailed
169 agents, including several with psychotropic and CNS
effects. Antidepressants, benzodiazepines, antiepileptics
and gabapentin and were used by 76, 66, 28 and 10% of
patients respectively and 23% were current smokers.
Minerbi’s group [27] also collected information regard-
ing drug use and smoking status, but little attention was
given to these as confounders, nor was detail regarding
the type, or extent of drug use or smoking provided.
Drugs of many kinds may impact gut bacteria and their
metabolism, and vice-versa: smoking is associated with
an altered gut microbial profile [48] and the Ruminococ-
cus genus (which was overexpressed in Clos-Garcia’s pa-
tient group) can impact antidepressant metabolism,
drugs which also alter the gut microbiota [49].
The understanding of the wide-reaching role of gut
bacteria in a plethora of metabolic processes and health
conditions has advanced significantly in recent years.
The advent of deep sequencing of the microbiome has
enabled a new era of discovery which is rapidly evolving.
Due to the limited number of studies evaluating the
composition of the gastrointestinal microbiota in our re-
sults, the heterogeneity of techniques used, variance in
findings, and issues around drug use, it is difficult to
draw any firm conclusions regarding microbiome alter-
ations in this patient population. This Pandora’s box is
of intricate complexity [50], such that meaningful results
would possibly be best obtained by studying these fac-
tors in a much larger, drug-naïve cohort. To date, no ex-
tensive analysis has been undertaken to simultaneously
evaluate the composition of the gastrointestinal tract
microbiota, its metabolites, luminal neurotransmitters
and brain neurochemistry in people with fibromyalgia.
Future studies should consider such analyses.
Metabolomics
Several variations in metabolomic markers suggest al-
tered microbial metabolism, but these are not consistent
across the studies. The previously identified problems
regarding the impact of drug intake and different dietary
patterns in the patient populations confounds results.
Alterations in levels of short chain fatty acids (SCFA)
suggest a role for altered bacterial populations, though
few, and at times conflicting, associations were reported.
Higher serum butyrate was reported by Minerbi, which
is consistent with increased urinary butyrate seen in
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Malatji’s study but is at odds with the lower expression
of butyrate-producers reported by both Minerbi and
Clos-Garcia. Interestingly, lower levels of butyrate-
producing bacteria are reported in IBS [51], which may
be a reflection of its roles in regulating the colonic mu-
cosa, intestinal motility and modulating visceral hyper-
sensitivity [52]. As such, these butyrate alterations in
fibromyalgia warrant further investigation.
It is unclear if the elevated urinary lactate reported by
Malatji study [53] was the L-isomer (which is endogen-
ously produced in muscle metabolism), the D-form,
which is primarily from exogenous (bacterial) sources
[54] or both. D-lactic acidosis is a serious condition, as-
sociated with metabolic acidosis and encephalopathy.
While no evidence exists that sub-clinical levels of D-
lactate may contribute to other conditions, Rao et al.
[55] maintain that mild cognitive symptoms produced
by oral administration of glucose are attributable to the
intestinal production of D-lactate. Dyscognition is a
common symptom in fibromyalgia [56] and Malatji’s
group did not report correlations in this domain with
lactate.
The authors predicted succinate to be human in ori-
gin, as it is a metabolite of the Krebs Cycle [24]. How-
ever, gut bacteria also produce succinate from fibre,
which is subsequently metabolised to propionate [57].
How the origin of succinate was determined to be hu-
man is unclear.
A notable strength of the work by Malatji et al., is the
range of controls, including family members and cohabi-
tants, allowing the researchers to consider shared factors
that may influence results. However, scant information
on drug use was provided in their reports [24, 25], nor
was this controlled for, which is a significant limitation.
The overall diversity of gut microbiota, various influ-
ences on it and the resultant metabolites within any one
population group present significant research challenges.
The per os intake of any substrate or metabolite may in-
crease populations of any organism able to consume it
[42], and as such, measures of metabolites only give part
of the picture. The use of both metagenomics and meta-
transcriptonomics in future studies may illuminate this
issue.
Other biomarkers
Intestinal Hyperpermeability
Goebel et al’s findings suggesting increased IP in both
fibromyalgia and CRPS should be interpreted with caution
[19]. The study protocol permitted participants to take
non-steroidal anti-inflammatory drugs (NSAIDs) up to 48
h before and aspirin until commencing the study. Use of
both these agents is associated with increased IP [58, 59].
Accordingly, higher levels of IP could reasonably be ex-
pected to occur secondary to use of the medications, but
neither actual drug intake relative to test commencement,
nor other factors known to be associated with altered IP
were reported. Furthermore, Goebel’s study solution con-
tained 10 g lactulose, 5 g mannitol and 20 g sucrose, and
as a solution containing a much lower dose of lactulose
and mannitol (5 g and 1 g respectively) can arrive in the
colon within 2 h [60], the reliability of prediction of small
intestinal permeability within this time-frame requires fur-
ther investigation. Notably absent was a discussion about
diarrhoea reported in fibromyalgia patients following this
test [19], which could be related to osmotic effects of the
saccharide load, or fermentation of same by bacteria.
While a recent systematic review found relationships be-
tween increased IP and several chronic conditions [61],
the validity of sugar-recovery tests as measures of IP and
the applicability of increased IP to aberrations in human
health beyond CD and inflammatory bowel diseases re-
mains uncertain [62].
We commented previously on succinate, one of the me-
tabolites contributing to differentiation of fibromyalgics
and healthy controls, reported by Malatji (2017) [24].
Additionally, elevated circulating succinate [24] has been
reported in patients with SIBO [63], IBS [64] H. pylori in-
fection [65] and is associated with increased IP [66], indi-
cating a gut-mediated inflammatory process. Whether any
of these connections can be made for fibromyalgia pa-
tients with increased IP requires investigation.
Small intestinal bacterial overgrowth
The association between a positive hydrogen breath test
and fibromyalgia [17] (Table 5), should be interpreted
within the context of the limitations of the test, testing
procedures and diagnostic criteria used. The authors
regarded a normal breath test as having no rise in hydro-
gen or methane before 90 min of administration of lactu-
lose, with “a definitive rise never more than 20 ppm”
over 3 h of testing. Accordingly, most subjects would be
expected to meet SIBO criteria, as lactulose is expected
to initiate fermentation on arrival in the colon, which
typically occurs within 100 mins [67]. Current criteria
specify a diagnostic rise should occur before 90 min [68].
While hydrogen and methane were both measured in
Pimentel’s 2004 study [17], test data was not tabulated
and only hydrogen results were presented and discussed.
An association between fibromyalgia and SIBO was re-
ported by Pimentel’s group in 2001 [69], a paper not in-
cluded in our review due to unclear criteria for the
diagnosis of both fibromyalgia and SIBO.
Fibromyalgics present with constipation at up to double
the rate of those with diarrhoea [11, 70], which correlates
with severity of fibromyalgia symptoms [70]. Constipation
is associated with higher methane production [71], yet
both Pimentel’s studies reported elevations in hydrogen
gas [17, 69]. Despite the 2004 study being remarkable for
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its 100% detection rate of SIBO in fibromyalgics, to our
knowledge no further studies have confirmed this
relationship.
Strengths & Limitations
A significant strength of this review is our requirement for
clear and accepted criteria for the diagnosis of fibromyal-
gia. However, methodical differences, inconsistency in the
testing methods used, inappropriate drug use and the in-
clusion of controls with diseases that were unaccounted
pose limitations to our findings.
Oxidative stress markers, neurotransmitters or amino
acids associated with pain signaling and neurological func-
tion were not included in our search terms. As alterations
in several neurotransmitters, including serotonin and glu-
tamate, have been implicated in fibromyalgia [7, 41] and
bacteria may be involved in their synthesis [72], it could
be argued that these terms should have been included.
While some papers reporting these were picked up in our
search, we determined that, as neurochemicals were not
targeted in our search terms, the studies identified would
not provide adequate substance for inclusion in a compre-
hensive review focusing on biomarkers associated with
gastrointestinal dysfunction.
Despite these limitations and the heterogeneity of the
studies included, preliminary findings suggest that gastro-
intestinal microbiome-targeted interventions may improve
clinical and/or laboratory measures related to the symp-
toms of fibromyalgia.
Conclusions
The findings of this review suggest the relationship be-
tween the gut microbiome and the pathophysiology of
fibromyalgia is a largely underexplored area. Despite the
limitations of the included studies, there are several indi-
cations that associations between the composition and
metabolism of the gastrointestinal microbiota and fibro-
myalgia may exist. As such, well-designed studies that
employ the latest technology and accepted diagnostic
testing practices while accounting for confounding fac-
tors are warranted.
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